Biomea Fusion, Inc.
NASDAQ:BMEABiotechnology
Healthcare
$0.74 -2.50%
-$0.03 today
- Market cap
- $53.18M
- Beta
- -0.33
- P/E (TTM)
- -1.9
- EPS (TTM)
- -$0.62
52W Low $0.87High $2.99
Volume 3.50M
Average 1.52M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$70.37M
FY 2025 · Annual
Investing Cash Flow
$0.00
FY 2025 · Annual
Financing Cash Flow
$67.90M
FY 2025 · Annual
+3971.0% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (41.57M) | (81.83M) | (117.26M) | (138.43M) | (61.8M) |
| Depreciation & Amortization | 249K | 691K | 1.52M | 1.75M | 1.41M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 6.23M | 10.34M | 14.13M | 19.09M | 9.52M |
| Change in Working Capital | (1.57M) | 7.67M | 2.33M | (5.15M) | (3.7M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 640K | 2.96M | 2.56M | 6.09M | (9.7M) |
| Other Working Capital | (2.21M) | 4.71M | (232K) | (11.24M) | 6M |
| Other Non-Cash Items | 1.22M | 715K | 2.69M | 2.84M | (15.81M) |
| Operating Cash Flow | (35.44M) | (62.42M) | (96.59M) | (119.89M) | (70.37M) |
| Capital Expenditures | (3.17M) | (1.03M) | (3.37M) | (362K) | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (38.49M) | 0 | 0 | 0 | 0 |
| Sales of Investments | 8.31M | 28.37M | 1.15M | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (33.35M) | 27.34M | (2.22M) | (362K) | 0 |
| Debt Repayment | (36K) | 0 | 0 | 0 | 0 |
| Common Stock Issued | 153.22M | 0 | 161.8M | 1.67M | 67.9M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 1.24M | 2M | 0 | 0 |
| Financing Cash Flow | 153.19M | 1.24M | 163.8M | 1.67M | 67.9M |
| Effect of Forex Changes | (351K) | 0 | 0 | 0 | 0 |
| Net Change in Cash | 84.04M | (33.84M) | 64.99M | (118.59M) | (2.47M) |
| Free Cash Flow | (38.61M) | (63.45M) | (99.96M) | (120.26M) | (70.37M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$61.8M
+ D&A$1.4M
+ Stock-Based Comp$9.5M
+ Deferred Tax$0
- Working Capital-$3.7M
- Other Non-Cash-$15.8M
= Operating Cash Flow-$70.4M
- Capex$0
= Free Cash Flow-$70.4M
Analysis
FY2025 free cash flow is -$70.4M. FCF conversion is 113.9% of net income. Operating cash flow was -$70.4M, with capex of $0. The largest bridge item is Other Non-Cash at -$15.8M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Oct 14, 2026 | |
| 424B5 | 424B5 filing | Sep 22, 2026 | |
| 8-K | Current report | Sep 22, 2026 | |
| 10-Q | Quarterly report | Aug 5, 2026 | |
| 8-K | Current report | Aug 5, 2026 |
Does BMEA generate free cash flow?
Biomea Fusion, Inc. (BMEA) generated -$70.37M of free cash flow in fiscal 2025.
How much operating cash flow does BMEA produce?
Operating cash flow was -$70.37M, before capital expenditures of $0.00.
Continue the stock analysis
Jump to another research area for this company.